Scandion Oncology (Scandion) will publish its yearend 2021 report on Thursday, February 17, 2022 before 08:00 CET.
Scandion Oncology’s executive management will host a webcast and conference call the same day at 08:30 CET presenting the results and a company update.
At the end of the presentation there will be a Q&A session.
Access to the event can be obtained as follows:
LIVE access on Thursday February 17, 2022 at 08:30 CET
For further information please contact:
Mads Kronborg, Head of External Communication
Phone: +45 6051 4955
The information was provided by the contact person above for publication on February 10, 2022, at 08.30 CET.
Scandion Oncology A/S, the Cancer Drug Resistance Company, is a clinical phase II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add-on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate, SCO-101, is currently in clinical phase II. The Company is targeting cancer drug resistance in various treatment modalities including chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden. Ticker: SCOL.
Västra Hamnen Corporate Finance is the Company’s certified advisor on Nasdaq First North Growth Market and can be reached at email@example.com or +46 (0) 40 200 250.